Literature DB >> 9045921

Targeted elimination of cells expressing the high-affinity receptor for IgE (Fc epsilon RI) by a Pseudomonas exotoxin-based chimeric protein.

A Fishman1, H Lorberboum-Galski.   

Abstract

The interaction between IgE and its high-affinity receptor Fc epsilon RI found on mast cells and basophils is the primary effector pathway in allergic response. To achieve a targeted elimination of cells expressing Fc epsilon RI receptors, we constructed a chimeric protein in which a Fc fragment of mouse IgE is attached to a truncated form of Pseudomonas exotoxin (PE). To prepare the targeting moiety, we used a DNA sequence corresponding to amino acids 301-437, representing 30 residues of domain 2 and domain 3 of the mouse IgE constant region. This sequence was fused at the 5' of a cDNA encoding PE40, a truncated form of PE lacking the cell binding domain. The chimeric protein, termed Fc(2'-3)-PE40, was expressed in Escherichia coli and partially purified. The protein is highly cytotoxic to mouse mast cell lines and bone marrow-derived primary mast cells. This cytotoxicity is specific, as it could be blocked upon addition of whole IgE. Moreover, the protein had no effect on other cell lines of hemopoietic origin. The Fc(2'-3)-PE40 chimeric protein offers a new approach to the treatment of allergic disorders.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9045921     DOI: 10.1002/eji.1830270220

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   6.688


  2 in total

1.  Targeted Fc2'-3-PE40 chimeric protein abolishes passive cutaneous anaphylaxis in mice.

Authors:  A Fishman; D Prus; R Belostotsky; H Lorberboum-Galski
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

2.  Mast Cell Targeted Chimeric Toxin Can Be Developed as an Adjunctive Therapy in Colon Cancer Treatment.

Authors:  Shan Wang; Linmei Li; Renren Shi; Xueting Liu; Junyan Zhang; Zehong Zou; Zhuofang Hao; Ailin Tao
Journal:  Toxins (Basel)       Date:  2016-03-11       Impact factor: 5.075

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.